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Abstract
Introduction: We previously demonstrated that 1 or 5 mg per day of tamoxifen (T) given for four weeks before
surgery reduces Ki-67 in breast cancer (BC) patients to the same extent as the standard 20 mg/d. Given the long
half-life of T, a weekly dose (10 mg per week (w)) may be worth testing. Also, raloxifene (R) has shown Ki-67
reduction in postmenopausal patients in a preoperative setting, but data in premenopausal women are limited.
We conducted a randomized trial testing T 10 mg/w vs. R 60 mg/d vs. placebo in a presurgical model.
Methods: Out of 204 screened subjects, 57 were not eligible, 22 refused to participate and 125 were included in
the study. The participants were all premenopausal women with estrogen receptor-positive BC. They were
randomly assigned to either T 10mg/w or R 60 mg/d or placebo for six weeks before surgery. The primary
endpoint was tissue change of Ki-67. Secondary endpoints were modulation of estrogen and progesterone
receptors and several other circulating biomarkers.
Results: Ki-67 was not significantly modulated by either treatment. In contrast, both selective estrogen receptor
modulators (SERMs) significantly modulated circulating IGF-I/IGFBP-3 ratio, cholesterol, fibrinogen and antithrombin
III. Estradiol was increased with both SERMs. Within the tamoxifen arm, CYP2D6 polymorphism analysis showed a
higher concentration of N-desTamoxifen, one of the tamoxifen metabolites, in subjects with reduced CYP2D6
activity. Moreover, a reduction of Ki-67 and a marked increase of sex hormone-binding globulin (SHBG) were
observed in the active phenotype.
Conclusions: A weekly dose of tamoxifen and a standard dose of raloxifene did not inhibit tumor cell proliferation,
measured as Ki-67 expression, in premenopausal BC patients. However, in the tamoxifen arm women with an
extensive phenotype for CYP2D6 reached a significant Ki-67 modulation.
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Introduction
Presurgical trials offer real ‘windows of opportunity’ to
study tissue biomarkers and their modulation in response
to drugs. The effort to study and validate surrogate bio-
markers is never wasted since it may lead to better
characterization of the tumor response, personalization
of adjuvant treatment, and the design of new prevention
strategies. The administration of selective estrogen recep-
tor modulators (SERMs) for a period of one to four
weeks has been shown to induce a significant antiproli-
ferative effect in estrogen receptor (ER)-positive breast
cancers [1,2]. Moreover, we have shown that 5 mg and
even 1 mg of tamoxifen maintains a similar antiprolifera-
tive effect compared to the standard dose [3]. Recently,
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the notion has been reinforced that the Ki-67 labeling
index (LI) after a short treatment has prognostic implica-
tions for disease-free survival and also for overall survival
[4,5].
Tamoxifen is the main drug that is able to reduce
breast cancer (BC) risk, but its adverse events have so
far precluded the uptake as a preventive agent [6]. The
Food and Drug Administration (FDA) has approved
raloxifene for the same indications as tamoxifen, though
only for postmenopausal women. Raloxifene has shown
an overall better toxicity profile, but a reduced activity
against intraepithelial lesions [7]. Recently, an aromatase
inhibitor (exemestane) has also been shown to signifi-
cantly lower BC risk again in postmenopause [8].
Seeking a better tamoxifen risk/benefit ratio in the pre-
vention setting, we have been studying lower dose tamoxi-
fen activity. Since the drug has a long half-life, a weekly
dose might be preferred by healthy women instead of a
daily administration. As previously shown, in phase II clin-
ical trials, low-dose tamoxifen (down to 10 mg a week)
can favorably modulate circulating biomarkers either in
healthy women on hormone replacement therapy, [9], or
in women operated on for an ER-positive intraepithelial
neoplasia [10].
With this rationale, we performed a randomized presur-
gical clinical trial with tamoxifen (10 mg a week) or raloxi-
fene (standard dose) versus placebo in premenopausal
women with ER-positive early breast cancer. This trial had
two main issues to be addressed: does a weekly dose of
tamoxifen show an antiproliferative effect on breast cancer
relative to placebo? Does raloxifene uphold efficacy and
safety in premenopausal women? The primary endpoint
was Ki-67 LI modulation. Several other secondary end-
points were measured including circulating breast cancer
risk biomarkers, such as insulin-like growth factor (IGF)
system and hormone levels; cardiocirculatory biomarkers
such as fibrinogen, antithrombin III, C-reactive protein
(CRP) and cholesterol; bone metabolism biomarkers, in
particular C-telopeptide (CTX) and osteocalcin.
Material and methods
Study design
This monoinstitutional study was conducted from 2004 to
2009. It is a three-arm randomized double-blind clinical
trial in premenopausal women with confirmed hormone-
responsive breast cancer. The three arms are: raloxifene
60 mg/day versus tamoxifen 10 mg/week versus placebo
in a 2:2:1 ratio for six weeks. By the time the study was
implemented, at the European Institute of Oncology, there
was a waiting time for early-stage breast cancer surgery of
approximately six to eight weeks. The study (IEO number
162, register number ISRCTN86894592) and all amend-
ments during its conduct were approved by the Institu-
tional Review Board (the European Institute of Oncology
Ethical Committee), and all subjects gave their written
informed consent. Tumor biopsy and blood samples were
taken to check eligibility criteria and were stored for end-
point analysis before the systemic treatment began. Blood
samples and breast tissue were taken again at surgery.
One hundred and twenty-five premenopausal patients
were included in the study. The primary endpoint was
Ki-67 LI tissue change. Secondary endpoints were the
assessment of the changes in ER and progesterone recep-
tor (PgR) expression, and other circulating biomarkers.
Inclusion criteria were: female, aged 18 years or older;
performance status = 0 (SWOG); histologically con-
firmed ER+ primary breast cancer; stage T1-2, N0-1, M0
or women with larger tumors refusing neoadjuvant
treatment before surgery; no previous breast cancer
treatment; written informed consent.
Exclusion criteria were: patients eligible for chemother-
apy and/or endocrine neoadjuvant therapy; evidence of
previous superficial or deep venous thrombosis or other
major thromboembolic events (pulmonary embolism,
stroke, and so on); current anticoagulant therapy; moder-
ate to severe alteration in hematologic profile, hemostasis,
renal and hepatic metabolism; clinically active peptic ulcer
or gastroenteric disease; severe retinal disease; severe
endometriosis (grade III to IV) or other proliferative disor-
ders of the endometrium; clinically active neurologic or
psychiatric disease; other medical contraindications
according to the investigator; other coexisting malignan-
cies or malignancies diagnosed within the last five years
with the exception of basal cell carcinoma or in situ cervi-
cal cancer; pregnancy or current breast-feeding (women of
child-bearing potential must have had a negative preg-
nancy test within seven days before the start of the study
treatment).
Treatment compliance was monitored by pill count,
the calendar filled out by the patient, and drug plasma
concentrations.
Sampling of biological specimens
Fasting blood samples were taken preferably between 8
and 10 a.m. at baseline and on the day before surgery.
EDTA blood samples were collected and stored unpro-
cessed in aliquots in the freezer at -80°C until DNA
extraction was performed. Serum and plasma were sepa-
rated by 10 minute centrifugation at 1350 × g and stored
as aliquots at -80°C until assayed for biomarkers.
Prior to randomization two sequential core biopsies of
the primary tumor were performed percutaneously with a
14-gauge needle after local anesthetic was administered.
The location of the biopsy was chosen on the basis of the
involved area of the breast and the consequent surgical
incision. At the time of surgery, a representative sample of
the cancerous excision tissue was obtained, together with
a specimen of the contiguous normal tissue.
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Assay methods
Circulating biomarkers
IGF-I and insulin-like growth factor-binding protein 3
(IGFBP-3) levels were determined on serum samples by
a solid-phase enzyme-labeled chemiluminescent immu-
nometric assay on the Immulite 2000 Siemens analyzer
(Siemens AG, Erlangen, Germany). The analytical sensi-
tivity of the test was 20 ng/mL for IGF-I and 0.1 μg/mL
for IGFBP-3. Total cholesterol, high-density lipoprotein
(HDL) cholesterol, and triglycerides serum levels were
determined by enzymatic colorimetric methods with a
Cobas Integra (Roche Diagnostics S.p.A., Monza, Italy),
a fully mechanized multichannel analyzer for routine
clinical chemistry purposes. Methods were performed
according to specific instructions. Low-density lipopro-
tein (LDL) cholesterol was obtained according to the
Friedewald formula (LDL cholesterol = total cholesterol -
HDL cholesterol - (triglycerides/5)) [11]. Plasma fibrino-
gen and antithrombin III were assayed on plasma citrate
samples using the ACL Elite Pro Analyzer (Instrumenta-
tion Laboratory, Bedford, MA, USA). In this assay, clot
detection is performed using a photo-optical technology.
Serum concentration of sex hormone-binding globulin
(SHBG was measured by a solid-phase, two-site chemilu-
minescent immunometric assay on the Immulite 2000
Siemens automated analyzer. The sensitivity of the assay
was 0.02 nm//L. High-sensitivity C-reactive protein (hs-
CRP) was determined by the enzymatic turbidimetric
method on the Cobas Integra analyzer. The sensitivity
of the test was 0.1 mg/L. Serum CTX and osteocalcin,
estradiol and testosterone were determined by an elec-
trochemiluminescent immunometric assay (Roche Diag-
nostics S.p.A., Monza, Italy) designed for the Cobas
e411 automated analyzer. The sensitivity of the assays
was 0.01 ng/mL and 0.50 ng/mL for CTX and osteocal-
cin, and 5 pg/mL and 0.025 ng/mL for estradiol and tes-
tosterone, respectively.
With the exception of the lipid profile, fibrinogen and
antithrombin III, which were determined on fresh speci-
mens, pre- and posttreatment serum samples obtained
from each subject were simultaneously assayed on frozen
samples to eliminate the effects of interassay variation. In
these assays, in addition to the specific control samples
that come with the assay kits, an in-house pooled control
sample of serum obtained from healthy donors was used
to monitor the coefficient of variation between assays.
Tamoxifen citrate and 4-hydroxytamoxifen (4-OHtam)
were purchased from Sigma-Aldrich (Steinheim, Ger-
many), the internal standard deuterated 5-tamoxifen
(D5tam) and tamoxifen-N-oxide (tamNox) from Beta
Chem Inc. (Kansas, USA), and 4-hydroxy-N-desmethylta-
moxifen (endoxifen) from Sintef Materials and Chemistry
(Oslo, Norway). N-desmethyltamoxifen (N-desTam) and
N-desdimethyltamoxifen (N-desDTam) were gifts from
the Pharmaceuticals Division of Imperial Chemical
Industries PLC (Macclesfield, UK). To determine the
concentrations of tamoxifen and its metabolites, a high-
pressure liquid chromatography-tandem mass spectro-
metry system was used [12,13]. The assay was modified
to improve the sensitivity by changing the API 2000/
Qtrap mass spectrometry system from Applied Biosys-
tems (AB MDS Sciex, Concord, Canada) to the API 4000,
equipped with TurboIonSpray.
Pathology and immunohistochemistry
Biopsy and surgical specimens were fixed in 10% neu-
tral-buffered formalin for 6 to 8 hours before being
embedded in paraffin. Sections (4 micron thick) were
cut and stained with hematoxylin and eosin. Consecu-
tive serial sections were used for immunohistochemical
determinations. Expressions of ER, PgR, Ki-67, human
epidermal growth factor receptor 2 (Her2)/neu were
determined by immunohistochemistry (IHC). Briefly,
dewaxed tumor sections were pretreated with 3% hydro-
gen peroxide for 5 minutes to block endogenous peroxi-
dase activity and then treated with a solution of 0.001
M EDTA (pH 8.0) at 99°C for 20 minutes to retrieve
antigens. The tumor sections were then incubated with
primary mouse monoclonal antibodies to ER (clone
1D5, 1:100 dilution), PgR (clone 1A6, 1:800 dilution),
Ki-67 (clone Mib-1, 1:200 dilution), or with rabbit poly-
clonal antibody to the Her2/neu protein (1:3200 dilu-
tion). Tumor subtypes were classified by IHC into four
categories according to the 2011 St. Gallen criteria [14]:
luminal A, ER- or PgR-positive and Ki-67 <14%; luminal
B-, ER- or PgR-positive, HER2-positive and Ki-67 ≥14%;
HER2-positive, HER2 3+ or fluorescence in situ hybridi-
zation (FISH) amplified and ER- and PgR-negative; triple
negative, all three receptors negative.
Genotype analysis
Genomic DNA was extracted from whole blood specimens
with a QIAamp DNA blood kit (Qiagen, Valencia, CA,
USA). The INFINITI analyzer (AutoGenomics, Carlsbad,
CA, USA) was employed for CYP2D6 genotyping, accord-
ing to the manufacturer’s protocol. The test screens for
the following CYP2D6 allele variants: *2 (2850C>T) (nor-
mal activity); *3 (2549delA), *4 (1846G>A), *5 (CYP2D6
deleted), *6 (1707 delT), (no activity); *7 (2935A>C); *8
(1758G>T); *9 (2615_2617delAAG); *10 (100C>T); *12
(124G>A); *14 (1758G>A); *17 (1023C>T); *29
(1659G>A); *41A (2988G>A) (reduced activity), and *XN
(multiple CYP2D6). We classified the resulting phenotype
as poor metabolizers (PM) when there were nonfunctional
variants on both alleles; intermediate metabolizers (IM) if
there was at least a slow or nonfunctional allele; extensive
metabolizers (EM) when both alleles were normal; ultrara-
pid metabolizers (UM) when normal alleles were ampli-
fied. For the analysis we grouped EM + UM as active, and
IM + PM as reduced activity.
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Statistical analysis
In this phase II presurgical trial, we tested the difference
in the percentage change reduction in Ki-67 LI by treat-
ment. The primary endpoint of the study was to assess
drug efficacy, measured as Ki-67 LI percentage change
in patients treated for six weeks before surgery.
All randomized subjects were evaluated according to
the intention-to-treat approach. The statistical analysis
of the primary and secondary endpoints was the com-
parison between the median change from baseline to
surgery and between the treatment arms. Ki-67 values
were log-transformed to reach normality; this procedure
was adopted for other variables when necessary.
Two orthogonal contrasts were used to compare bio-
marker changes among treatment groups: any treatment
versus placebo and tamoxifen versus raloxifene. These
contrasts were specified a priori and are consistent with
the aims of the study.
The effect of potential covariates, such as age, body
mass index (BMI), tumor grade and size, and baseline
levels of circulating biomarkers, together with their
interactions with treatment were investigated through
the ANCOVA analysis.
As exploratory investigations, we evaluated the effect
of CYP2D6 phenotype on the variations of metabolites,
Ki-67 expression and other biomarkers, as a factor in
the ANOVA models, using the available data.
Median values, interquartile ranges and results from
nonparametric Wilcoxon tests were presented to investi-
gate differences among the treatment arms of subjects’
demographics and tumor characteristics at baseline,
when evaluated as continuous variables. Frequencies,
chi-squared or Fisher’s exact tests were used to present
and analyze the association between categorical
variables.
All statistical tests were two-sided. Analyses were per-
formed using SAS statistical software (version 9.0, SAS
Institute Inc, Cary, NC, USA).
Results
From February 2004 to November 2009, a total of 204
women were registered and assessed to determine their
eligibility for the study (Figure 1). Of those women,
57 were not eligible, a further 22 women refused to parti-
cipate in the study, and 125 women were randomized.
Subject demographics and tumor characteristics at base-
line are shown in Table 1. There were no statistically sig-
nificant differences among the three arms. Treatment
compliance was over 80% by pill count. Drug plasma levels
were measured and confirmed an adequate drug intake;
raloxifene levels ranged from 28 to 65.5 ng/mL. Tamoxi-
fen plasma concentration ranged from 7.68 to 11.7 ng/mL
and the endoxifen range was 2.52 to 4.1 ng/mL.
Endpoint tissue biomarkers
A weekly dose of 10 mg of tamoxifen did not show a
significant antiproliferative effect in premenopausal
women. Likewise, raloxifene had a similar null effect on
Ki-67 LI, the mean change being 0 in the three arms.
The P value was 0.78 and 0.76 for treatment vs. placebo
and tamoxifen vs. raloxifene, respectively (Table 2). Also
ER (data not shown) and PgR (Table 2) were not signifi-
cantly modulated by either drugs. For PgR, the median
change was 0 in the placebo and raloxifene arm,
whereas the tamoxifen group was 4.5 (P value 0.26 and
0.10 for treatment vs. placebo and tamoxifen vs. raloxi-
fene, respectively).
Circulating biomarkers
Both drugs showed a significant biologic effect on circu-
lating biomarkers. As BC risk biomarkers, IGF-1,
IGFBP-3, SHBG, estradiol, and testosterone were
assessed (see Table 3). Both SERMs significantly modu-
lated circulating IGF-1/IGFBP-3 ratio, the median
change was -0.01 in the tamoxifen group, -0.03 in the
raloxifene arm, and 0 in the placebo arm (P value for
treatment vs. placebo 0.008). Estradiol mean change was
27 and 29.5 for raloxifene and tamoxifen, respectively
(treatment vs. placebo P = 0.053).
No difference was observed between treatment and
placebo for SHBG, IGFBP-3, IGF-1 and testosterone.
There was a difference between the two SERMs for
IGFBP-3, with a greater increment of the binding pro-
tein with raloxifene, mean change 0.41 vs. 0.02 (tamoxi-
fen vs. raloxifene P = 0.046).
The following cardiovascular risk biomarkers were ana-
lyzed: cholesterol, fibrinogen, antithrombin III, and CRP
(see Table 4). With the exception of CRP, all the other
biomarkers were significantly modulated by treatment
compared to placebo. Cholesterol median change was
-12 and -7, antithrombin III was -7 and -8, fibrinogen -2
and -29.5 for tamoxifen and raloxifene, respectively. The
P value for treatment vs. placebo for cholesterol, fibrino-
gen, and antithrombin III was P < 0.0001, P = 0.017 and
P = 0.009, respectively. Fibrinogen showed a difference
also between the two SERMs, with a greater reduction by
raloxifene compared to tamoxifen (P = 0.017).
Table 4 also shows CTX and osteocalcin biomarkers
to investigate bone metabolism. Overall the treatment
did not lead to any significant modulation of the two
biomarkers. For CTX, we observed a median change of
-0.03 in the tamoxifen group and 0.02 in the raloxifene
arm, with a borderline significant difference between
them (P value 0.051 tamoxifen vs. raloxifene). Osteocal-
cin was unchanged in all three arms.
Genotype, phenotype and tamoxifen metabolites
Genotype analysis for CYP2D6 was performed in all the
subjects. The frequencies were respectively: tamoxifen
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arm 40% of EM, 48% of IM, 6% of PM, and 6% of UM;
raloxifene arm 32% of EM, 64% of IM, 4% of PM; pla-
cebo arm 36% of EM, 56% of IM, 8% of PM. Tamoxifen
and its metabolite concentrations were measured, and
the correlation with the phenotype was evaluated. The
phenotypes were grouped in two classes: active (EM +
UM) and with a reduced activity (IM + PM). As shown
in Figure 2a, a significant accumulation of N-desTam
Figure 1 Consort statement
Table 1 Subjects’ clinical characteristics at baseline.
Placebo
(25)
Raloxifene
(50)
Tamoxifen
(50)
Age
(Lower-upper quartile)
44
(42-47)
46
(42-49)
45
(41-49)
Age at menarche
(Lower-upper quartile)
13
(12-13)
12
(12-13)
12
(11-14)
Parity 1 2 2
Family history1
BC°- OC°°
5 - 1 15 - 1 11 - 3
Body mass index
(Lower-upper quartile)
22.9
(21.7-26.2)
22.2
(20.5-24.6)
22.2
(20.3-25.2)
Smoking
Never/former/current/
missing
14/3/8/0 28/10/11/1 24/5/21/0
Tumor size mm
(Lower-upper quartile)
22.0 (15-30) 22.5 (15.0-28.5) 21.5 (15.0-27.5)
Tumor grade
1/2/3/unknown2
7/7/5/6 3/23/7/17 3/22/8/17
HER2 overexpression %
No/yes
96/4 98/2 94/6
Luminal subtype %
A/B HER2 neg/B HER2 pos
36/60/4 20/78/2 27/67/3
1First or second degree relatives with °breast cancer (BC) or °°ovarian cancer (OC); 2not graded by the pathologist.
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Table 2 Median change of the Ki-67 labeling index and progesterone receptors
Variable Arm Baseline Surgery
Median IQR Median IQR Median change Contrast P
Ki-67 P 16 (9 to 22) 15 (10 to 23) 0 (-4 to 3) T vs. R P = 0.76
T 18 (14 to 28) 19.5 (12.5 to 26.5) 0 (-5 to 4) T + R vs. P P = 0.78
R 21.5 (15 to 27) 21 (15 to 25) 0 (-5 to 4)
PgR P 80 (65 to 95) 90 (60 to 95) 0 (0 to10) T vs. R P = 0.10
T 65 (10 to 90) 65 (22.5 to 92.5) 4.5 (-0.5 to 12.5) T + R vs. P P = 0.26
R 80 (45 to 90) 70 (20 to 90) 0 (-5 to 5)
ER P 90 (80 to 95) 90 (80 to 95) 0 (0 to 1) T vs. R P = 0.99
T 90 (80 to 90) 90 (80 to 95) 1 (0 to 5) T + R vs. P P = 0.82
R 90 (90 to 95) 90 (85 to 95) 0 (0 to 1)
IQR, interquartile range; P, placebo; T, tamoxifen 10 mg/week; R, raloxifene 60 mg/day; PgR, progesterone receptor; ER, estrogen receptor.
Table 3 Median change (interquartile range) of circulating biomarkers
Baseline Six weeks Change
Variable Treat. N Obs Median
IQR
Median
IQR
Median
IQR
Contrast1 P
IGF1 ng/mL P 25 146
(117 to 177)
151
(105 to 205)
-0.5
(-14.5 to 12)
T vs. R 0.87
R 50 134.5
(113 to 174)
126
(104 to 157)
-10.1
(-30.4 to 13)
T + R vs. P 0.15
T 50 137.5
(113 to 170)
137
(92.7 to 168)
-13
(-27 to 11)
IGFBP-3 µg/mL P 25 4.16
(3.75 to 4.76)
4.42
(3.79 to 4.84)
-0.09
(-0.29 to 0.22)
T vs. R 0.05
R 50 4.22
(3.84 to 4.71)
4.58
(4.07 to 5.11)
0.41
(0 to 0.69)
T + R vs. P 0.22
T 50 4.28
(3.72 to 4.73)
4.42
(3.87 to 4.78)
0.02
(-0.25 to 0.37)
IGF1/BP3 ratio P 25 0.18
(0.16 to 0.21)
0.18
(0.15 to 0.24)
0
(-0.03 to 0.02)
T vs. R 0.41
R 50 0.17
(0.15 to 0.21)
0.16
(0.12 to 0.17)
-0.03
(-0.05 to 0)
T + R vs. P 0.01
T 50 0.18
(0.15 to 0.2)
0.17
(0.13 to 0.19)
-0.01
(-0.04 to 0)
SHBG nmol/L P 25 65.9
(39 to 94)
53.5
(36 to 86)
-7.7
(-22 to 3.4)
T vs. R 0.92
R 50 63.45
(43.3 to 96.4)
78.1
(50.7 to 101)
7.7
(-7.3 to 18.5)
T + R vs. P 0.32
T 50 64.3
(47.8 to 80.4)
69.6
(51.7 to 86.8)
2.2
(-7.1 to 21.9)
Testosterone P 25 0.26
(0.17 to 0.34)
0.28
(0.16 to 0.35)
0.02
(-0.08 to 0.07)
T vs. R 0.90
ng/mL R 50 0.23
(0.16 to 0.32)
0.27
(0.18 to 0.36)
0.03
(-0.03 to 0.09)
T + R vs. P 0.10
T 50 0.23
(0.19 to 0.32)
0.27
(0.22 to 0.34)
0.02
(-0.02 to 0.09)
Estradiol ng/mL P 25 120.3
(51.4 to 167.4)
104.35
(45.1 to 179.4)
-9.6
(-99.6 to 91)
T vs. R 0.45
R 50 94.35
(41.9 to 147.4)
124.7
(65.5 to 209)
27
(-62.9 to 159.08)
T + R vs. P 0.05
T 50 103.25
(61.98 to 165.5)
160.7
(70.86 to 306.4)
29.5
(-37.3 to 179.8)
IQR, interquartile range; IGF, insulin-like growth factor; P, placebo; R, raloxifene 60 mg/day; T, tamoxifen 10 mg/week; IGFBP-3, insulin-like growth factor-binding
protein 3; SHBG, sex hormone-binding globulin.
*Contrast are between tamoxifen arm versus Raloxifene are and either treatment versus placebo.
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was present in the reduced activity group, the mean
plasma level of N-desTam was 19.9 in the reduced
group and 14.4 ng/mL in the active one (P = .05).
Endoxifen and 4-OHtam were not statistically different
in the two phenotype groups. Figure 2b shows the cor-
relation between phenotype and biomarker modulations.
We selected those which are more directly correlated
with breast cancer risk. Interestingly, the active pheno-
type showed a significantly different modulation in Ki-
67 with a median change of -2.5 in the active group and
+2.5 in the reduced one, while no difference in ER or
PgR expression was determined by the phenotype (data
not shown). Among the circulating biomarkers, SHBG
showed a significant difference in the active group as
compared to the reduced one (median change 8.35 and
2 P = 0.05), whereas estradiol and IGF-1/BP3 did not
show any changes between the groups (data not shown).
In order to confirm that these observations are due to
tamoxifen and phenotype interaction we also analyzed the
effect of the phenotype of the other two arms. Table 5
shows the lack of Ki-67 modulation in the no tamoxi-
fen treated subjects by phenotype, and the significant
tamoxifen - phenotype interaction (P = 0.01).
Discussion
The efficacy of tamoxifen in lowering breast cancer risk
has been confirmed in long-term follow-up of the main
chemoprevention trials [15]. In spite of these very strong
data, the use of tamoxifen in the clinical practice for
breast cancer prevention in high-risk women has shown
Table 4 Median change of circulating biomarkers.
Baseline Six weeks Change
Variable Treat. N Obs Median
IQR
Median
IQR
Median
IQR
Contrast1 P
Fibrinogen P 25 312.0
(273.0 to 340.0)
333.5
(276.0 to 354.0)
4.5
(-19.0 to 24.0)
T vs. R 0.02
mg/dL R 50 301.0
(254.0 to 334.0)
260.0
(230.0 to 288.0)
-29.5
(-61.0 to -5.0)
T + R vs. P 0.01
T 50 286.0
(247.0 to 319.0)
285.0
(243.0 to 312.0)
-2.0
(-20.0 to 12.0)
Antithrombin P 25 102.0
(98.0 to 109.0)
99.0
(93.0 to 104.0)
-1.0
(-5.0 to 4.0)
T vs. R 0.75
% R 50 103.0
(98.0 to 108.0)
94.0
(90.0 to 101.0)
-8.0
(-11.0 to -1.0
T + R vs. P 0.02
T 50 106.0
(98.0 to 114.0)
100.0
(92.0 to 106.0)
-7.0
(-16.0 to -1.0)
CRP P 25 0.6
(0.3 to 2.8)
0.8
(0.3 to 3.3)
0.0
(-0.1 to 0.6)
T vs. R 0.12
mg/dL R 50 1.0
(0.5 to 1.9)
0.6
(0.4 to 1.3)
-0.3
(-0.7 to 0.1)
T + R vs. P 0.21
T 50 0.7
(0.4 to1.2)
0.8
(0.4 to 1.3)
0.1
(-0.3 to 0.3)
Cholesterol P 25 199.0
(185.0 to 224.0)
225.5
(197.0 to 244.0)
13.5
(1.0 to 33.0)
T vs. R 0.30
mg/dL R 50 199.5
(179.0 to 222.0)
192.0
(168.0 to 215.0)
-7.0
(-23.0 to 5.0)
T + R vs. P <.0001
T 50 201.5
(180.0 to 220.0)
188.5
(171.0 to 200.0)
-12.0
(-18.0 to 0.0)
CTX ng/mL P 25 0.3
(0.2 to 0.4)
0.3
(0.2 to 0.3)
0.0
(-0.1 to 0.0)
T vs. R 0.05
R 50 0.3
(0.2 to 0.4)
0.3
(0.2 to 0.4)
0.0
(0.0 to 0.1)
T + R vs. P 0.58
T 50 0.3
(0.2 to 0.4)
0.3
(0.2 to 0.4)
0.0
(-0.1 to 0.0)
Osteocalcin P 25 16.9
(13.4 to20.3)
16.5
(13.1 to 22.5)
-0.5
(-1.9 to 2.2)
T vs. R 0.39
ng/mL R 50 17.9
(13.8 to 22.5)
16.8
(13.4 to 20.8)
-1.7
(-3.5 to 1.1)
T + R vs. P 0.32
T 50 16.0
(61.98 to 165.5)
15.3
(12.5 to 20.2)
-0.7
(-2.0 to 1.0)
1Change adjusted for baseline. CRP, C-reactive protein; CTX, C-telopeptide; IQR, interquartile range; P, placebo; R, raloxifene 60 mg/day; T, tamoxifen 10 mg/week.
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little increase. For postmenopausal women, raloxifene
showed substantial breast cancer risk reduction in the
STAR study [7], although inferior to tamoxifen during
follow-up [16]. As a preventive strategy, raloxifene may
have more appealing characteristics compared to
tamoxifen, since it has a better safety profile and is not
commercially labeled as an anticancer drug; both are
important aspects to consider in preventive care. It
would be very interesting to study and to extend the
raloxifene indications to premenopausal women.
Figure 2 CYP2D6 phenotype, tamoxifen metabolites and biomarkers modulation. (a) Tamoxifen and its major metabolite plasma level
based on CYP2D6 phenotypes. A significant accumulation of N-desmethyltamoxifen is noticed in the reduced activity phenotype. (b) Ki-67
labeling index (LI) and sex hormone-binding globulin (SHBG) modulation based on the different phenotypes. A significant decrease of Ki-67 LI
and an increase of SHBG can be seen in the active group.
Table 5 Tamoxifen versus no tamoxifen and phenotype interaction on Ki-67 modulation.
Variable Reduced Active
Tamoxifen
Median (Low/upper quartile)
No tamoxifen
Median (Low/upper quartile)
Tamoxifen
Median (Low/upper quartile)
No tamoxifen
Median (Low/upper quartile)
Ki-67 change 2.5 (-2/7) 0 (-5/2) -2.5 (-10/0) 0 (-1/4)
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The data obtained by presurgical studies are useful
tools not only in studying drug activity, but also in eval-
uating prognostic and predictive factors. This allows
improved tailoring of treatment both in the adjuvant
and the preventive setting [4,5,17].
In the preventive setting, our group is striving to
improve the risk-benefit profile of tamoxifen, investigat-
ing the minimal effective dose.
The main question of this study was whether 10 mg per
week of tamoxifen and standard dose raloxifene can
lower Ki-67 LI after six weeks of treatment in premeno-
pausal women operated on for ER-positive breast cancer.
The results here reported showed no effect of the two
drugs on Ki-67 LI. These data differ from a previous
study where the effect of low-dose tamoxifen (down to
1 mg/day) reduced Ki-67 LI in women with breast cancer
[3]. Also, PgR expression was not modulated by the treat-
ment; these data are consistent with a previous study by
Clarke et al. with tamoxifen at standard dose [1]. Two
aspects must be mentioned: first, the participants of the
previous study were mostly postmenopausal. Second,
although the cumulative dose of 10 mg per week is
greater than 1 mg per day, tamoxifen having an approxi-
mate eight-day half-life [18], the plasma concentration of
10 mg per week was lower compared to the concentra-
tion of 1 mg per day measured in the earlier study [3].
On the other hand, the tamoxifen plasma level reported
here is consistent with a previous study with the same
schedule. In that study, the drug was measured at three,
six, and twelve months [10].
According to our previous data [19], at this drug con-
centration the influence of CYP2D6 genotype shows a
significant difference only for N-desTam, the endoxifen
substrate, and not for endoxifen itself. Significantly higher
levels of the substrate were shown in the reduced enzyme
activity subjects. It was interesting to observe that,
although endoxifen concentration was not different in the
two phenotypes, the extensive metabolizers lowered Ki-67
LI and greatly increased SHBG. Since estradiol was not
differently modulated one can speculate that the extensive
phenotype may have a greater antagonistic activity com-
pared with the reduced one. Although CYP2D6 poly-
morphisms per se showed conflicting results at a clinical
level [20-23], they may be relevant for specific tamoxifen
biological activities and play a role in a broader picture as
suggested by Dunn et al. [24].
Similarly to tamoxifen, raloxifene has also showed a
Ki-67 LI reduction in a presurgical study; yet again, that
was in postmenopausal subjects only [2]. Other phase II
clinical trials have studied raloxifene in premenopausal
women. A first report showed a reduction in fibroglandu-
lar tissue volume detected by magnetic resonance imaging
(MRI), but the mammographic density was unchanged,
after one and two years of treatment [25]. The same group
showed that raloxifene significantly increased plasma level
of estradiol and SHBG [26]. Our results are consistent
with these data, moreover we have shown a reduction of
the IGF-1-BP3 ratio.
Little is known about raloxifene bioavailability: the
plasma concentration detected in our patients is rela-
tively high considering the peak reached with a single-
dose administration [27].
SERMs, tamoxifen in particular, have a quite complex
balance between agonist and antagonist effects. This is
influenced by several variables, such as dosage, target
tissue, expression coactivators, and hormonal milieu
[28-31]. Differences in menopausal status and dose
schedule in the population of the study may explain our
different results as compared to the previous trials. In
the NSABP-P1, tamoxifen was shown to be slightly less
effective in premenopausal subjects as compared to
postmenopausal women [32].
Although there was no effect on Ki-67 LI, a biological
drug activity is shown by the modulation of the circulating
biomarkers. On average, the treatment increased SHBG
and estradiol, and decreased the IGF-1/IGFBP-3 ratio as
compared to placebo. Cholesterol, antithrombin III, and
fibrinogen were significantly decreased by treatment. On
the other hand, no differences were observed on testoster-
one, CRP, osteocalcin, and C-telopeptide. Although the
circulating biomarkers were modulated by treatment, no
correlation with clinical outcome can be drawn. No major
differences between drugs were noticed on any surrogate
biomarkers, except for a slight increase of IGPBP-3 and a
substantial reduction of fibrinogen with raloxifene over
tamoxifen. These findings may suggest that the bioactivity
of low-dose tamoxifen is comparable to standard-dose
raloxifene.
Lacking any effect on primary endpoint, that is Ki-67 LI
reduction, it is difficult to support a definite preventive
role of a weekly dose of tamoxifen or raloxifene in preme-
nopause. However, the unchanged Ki-67 LI does not
necessarily means a lack of preventive activity. Our end-
point, cancer cell proliferation, is focused on a final step
along the pathological process. SERMs activity is certainly
broader than merely a cytostatic or cytotoxic effect.
Although both drugs modulate sex hormones, the IGF
system and other circulating biomarkers, none of these
have been validated as surrogate biomarkers for cancer
prevention. Tamoxifen, at such low doses, most probably
cannot successfully compete with ERs in the presence of
premenopausal estradiol levels. Considering our previous
and current studies, we are now focusing, in the preven-
tion setting, on tamoxifen at 5 mg per day. Raloxifene,
considering our data together with those of other studies,
may have biological activity in premenopausal women, but
its possible role in breast cancer prevention has to be still
confirmed.
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Conclusions
Tumor cell proliferation, in premenopausal breast can-
cer patients, was not reduced by a weekly low dose of
tamoxifen and standard dose of raloxifene. Yet, at a bio-
logical level, both drugs did show some activity, modu-
lating some circulating biomarkers. Interestingly,
subjects’ phenotype for CYP2D6 differentially modulated
the tamoxifen effect on Ki-67 and SHBG, showing an
enhancement of activity in the extensive phenotype
subjects.
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